Melanoma, a skin cancer that develops from pigment cells, has been studied intensively,
particularly in terms of the immune response to tumours, and has been used as a model for …

Cancer is associated with higher morbidity and mortality and is the second leading cause of
death in the US. Further, in some nations, cancer has overtaken heart disease as the …

Genome editing holds great potential for cancer treatment due to the ability to precisely
inactivate or repair cancer-related genes. However, delivery of CRISPR/Cas to solid tumours …

CD8+ cytotoxic T lymphocytes (CTLs) are preferred immune cells for targeting cancer.
During cancer progression, CTLs encounter dysfunction and exhaustion due to …

Cancer immunotherapies provide survival benefits in responding patients, but many patients
fail to respond. Identifying the biology of treatment response and resistance are a priority to …

T-cell–recruiting bispecific molecule therapy has yielded promising results in patients with
hematologic malignancies; however, resistance and subsequent relapse remains a major …

Immune-checkpoint inhibitors have revolutionized cancer therapy, yet many patients either
do not derive any benefit from treatment or develop a resistance to checkpoint inhibitors …

In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional
T cells are characterized by reduced proliferative capacity, decreased effector function, and …

The upregulation of immune checkpoint molecules, such as programmed cell death protein
1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4), on immune cells occurs during acute …

The failure of a massive influx of tumor-infiltrating T lymphocytes to eradicate tumor cells in
the tumor microenvironment is mainly due to the dysfunction of T cells hyporesponsive to …